ICLE 2022 | Treating multiple myeloma with cilta-cel in earlier settings
Angela Krackhard, MD, PhD, Technical University of Munich, Munich, Germany, provides her perspectives on the imminent approval of ciltacabtagene autoleucel (cilta-cel), an anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy for patients with multiple myeloma, in Europe. Cilta-cel recognizes two separate epitopes of BCMA, making it a very promising therapy for relapsed/refractory multiple myeloma pretreated with various proteosome inhibitors and antibodies. Prof. Krackhard additionally calls for further studies to assess cilta-cel in earlier lines of therapy to investigate whether they can reduce tumor load to prevent progression. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.
